



Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019

October 31, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2019-- [Seres Therapeutics, Inc.](https://www.businesswire.com/news/home/20191031005654/en/) (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 3577505. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent *C. difficile* infection. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma. SER-301, a next-generation rationally-designed live microbiome biotherapeutic candidate is in preclinical development for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191031005654/en/>

Source: Seres Therapeutics, Inc.

Seres Contact:

Carlo Tanzi, Ph.D., 617-203-3467
ctanzi@serestherapeutics.com